VINEETLABPharmaceuticals
Vineet Laboratories Ltd — Cash Flow Statement
₹29.06
+0.00%
Vineet Laboratories Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | 10.45 Cr | -9.40 Cr | -17.25 Cr | 7.63 Cr | — |
| Repayment Of Debt | -4.45 Cr | -5.87 Cr | 0.00 | 0.00 | — |
| Issuance Of Debt | 0.20 Cr | 19.08 Cr | 4.58 Cr | 14.04 Cr | — |
| Capital Expenditure | -1.05 Cr | -2.79 Cr | -7.63 Cr | — | — |
| End Cash Position | 0.31 Cr | 0.23 Cr | 0.63 Cr | 16.66 Cr | — |
| Other Cash Adjustment Outside Changein Cash | 1000.00 | — | 1000.00 | -1000.00 | — |
| Beginning Cash Position | 0.23 Cr | 0.63 Cr | 16.66 Cr | 0.75 Cr | — |
| Changes In Cash | 0.08 Cr | -0.40 Cr | -16.03 Cr | 15.91 Cr | — |
| Financing Cash Flow | -8.23 Cr | 8.43 Cr | 0.27 Cr | 11.96 Cr | — |
| Net Other Financing Charges | -1000.00 | -1000.00 | — | — | — |
| Interest Paid Cff | -3.98 Cr | -4.78 Cr | -3.38 Cr | -2.09 Cr | — |
| Net Issuance Payments Of Debt | -4.25 Cr | 13.21 Cr | 4.58 Cr | 14.04 Cr | — |
| Net Short Term Debt Issuance | -3.82 Cr | 13.90 Cr | 0.41 Cr | 0.00 | — |
| Short Term Debt Payments | -3.82 Cr | — | — | — | — |
| Net Long Term Debt Issuance | -0.43 Cr | -0.69 Cr | 4.17 Cr | 14.04 Cr | — |
| Long Term Debt Payments | -0.63 Cr | -5.87 Cr | 0.00 | 0.00 | — |
| Long Term Debt Issuance | 0.20 Cr | 5.19 Cr | 4.17 Cr | 14.04 Cr | — |
| Investing Cash Flow | -3.18 Cr | -2.22 Cr | -6.69 Cr | -3.68 Cr | — |
| Net Other Investing Changes | -0.15 Cr | 0.10 Cr | 1000.00 | -1000.00 | — |
| Interest Received Cfi | -1.99 Cr | 0.46 Cr | 0.12 Cr | 0.16 Cr | — |
| Net PPE Purchase And Sale | -1.05 Cr | -2.79 Cr | -7.63 Cr | 0.00 | — |
| Purchase Of PPE | -1.05 Cr | -2.79 Cr | -7.63 Cr | 0.00 | — |
| Operating Cash Flow | 11.49 Cr | -6.61 Cr | -9.62 Cr | 7.63 Cr | — |
| Taxes Refund Paid | -0.12 Cr | -0.25 Cr | -2.99 Cr | -3.18 Cr | — |
| Change In Working Capital | 23.95 Cr | -13.50 Cr | -14.63 Cr | -2.43 Cr | — |
| Change In Other Current Liabilities | 1.34 Cr | -9.86 Cr | 5.58 Cr | -1.33 Cr | — |
| Change In Other Current Assets | 3.35 Cr | -1.55 Cr | 3.44 Cr | -9.82 Cr | — |
| Change In Payable | 1.36 Cr | -2.63 Cr | -26.26 Cr | 4.10 Cr | — |
| Change In Inventory | -0.58 Cr | -3.22 Cr | -2.63 Cr | -3.85 Cr | — |
| Change In Receivables | 18.36 Cr | 3.56 Cr | 5.07 Cr | 6.52 Cr | — |
| Other Non Cash Items | 5.96 Cr | 4.32 Cr | 3.26 Cr | 1.89 Cr | — |
| Depreciation And Amortization | 2.50 Cr | 2.52 Cr | 2.37 Cr | 2.02 Cr | — |
| Depreciation | 2.50 Cr | 2.52 Cr | 2.37 Cr | 2.02 Cr | — |
| Gain Loss On Investment Securities | -0.02 Cr | -0.05 Cr | 22000.00 | — | — |
| Net Foreign Currency Exchange Gain Loss | -42000.00 | -68000.00 | 0.34 Cr | 0.00 | — |
| Net Income From Continuing Operations | -20.78 Cr | 0.36 Cr | 2.03 Cr | 9.35 Cr | — |
| Common Stock Dividend Paid | — | 0.00 | -0.92 Cr | 0.00 | 0.00 |
| Short Term Debt Issuance | — | 13.90 Cr | 0.41 Cr | 0.00 | — |
| Net Investment Purchase And Sale | — | 0.10 Cr | 0.83 Cr | -3.84 Cr | -7.85 Cr |
| Cash Dividends Paid | — | — | -0.92 Cr | — | — |
| Sale Of Investment | — | — | 0.83 Cr | 0.00 | 0.00 |
| Purchase Of Investment | — | — | 0.00 | -3.84 Cr | -7.85 Cr |
| Repurchase Of Capital Stock | — | — | — | 0.00 | 0.00 |
| Issuance Of Capital Stock | — | — | — | 0.00 | 8.81 Cr |
| Effect Of Exchange Rate Changes | — | — | — | 0.00 | 0.00 |
| Preferred Stock Dividend Paid | — | — | — | 0.00 | 0.00 |
| Net Preferred Stock Issuance | — | — | — | 0.00 | 0.00 |
| Preferred Stock Issuance | — | — | — | 0.00 | 0.00 |
| Net Common Stock Issuance | — | — | — | 0.00 | 8.81 Cr |
| Common Stock Payments | — | — | — | 0.00 | 0.00 |
| Common Stock Issuance | — | — | — | 0.00 | 8.81 Cr |
| Dividends Received Cfi | — | — | — | 0.00 | 0.00 |
| Net Investment Properties Purchase And Sale | — | — | — | 0.00 | 0.00 |
| Sale Of Investment Properties | — | — | — | 0.00 | 0.00 |
| Purchase Of Investment Properties | — | — | — | 0.00 | 0.00 |
| Net Business Purchase And Sale | — | — | — | 0.00 | 0.00 |
| Sale Of Business | — | — | — | 0.00 | 0.00 |
| Purchase Of Business | — | — | — | 0.00 | 0.00 |
| Net Intangibles Purchase And Sale | — | — | — | 0.00 | 0.00 |
| Purchase Of Intangibles | — | — | — | 0.00 | 0.00 |
| Sale Of PPE | — | — | — | 0.00 | 0.00 |
| Stock Based Compensation | — | — | — | 0.00 | 0.00 |
| Deferred Tax | — | — | — | -3.18 Cr | 1.28 Cr |
| Gain Loss On Sale Of PPE | — | — | — | 0.00 | 0.00 |
| Gain Loss On Sale Of Business | — | — | — | 0.00 | 0.00 |
| Amortization Cash Flow | — | — | — | — | 0.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Vineet Laboratories Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.